Most of what you read about GHK-Cu — the copper-binding tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II) — comes from experiments where the peptide is dissolved in fluid and poured directly onto cells. Human skin does not work like that. If you're asking what is GHK-Cu and whether the copper peptide research justifies the marketing, the most useful question isn't "does it do anything in a dish?" (it clearly does) but "how much of that survives the trip through the stratum corneum?" That gap — between a pipette and a face — is where most of the hype quietly lives.

Note on sourcing: our usual live search wasn't available for this piece, so we've kept every claim below to material we can point to in the published reviews and to Australian regulatory positions listed in Sources. Where a figure is contested or comes from an interested party, we say so.

Where the impressive GHK-Cu numbers actually come from

The single most-quoted claim in copper peptide marketing is that GHK "resets" thousands of human genes. That figure — commonly cited as roughly 4,192 genes shifted toward a healthier expression pattern — comes from analyses of gene-expression databases built on cultured human cell lines exposed to GHK, summarised in review papers by Loren Pickart and colleagues. It is a real, published analysis. It is also, on its own terms, in vitro: cells in plastic, bathed in peptide, measured at the transcript level. Gene expression changes are a mechanism signal, not a clinical outcome. Nothing in that dataset tells you a serum made someone's skin measurably firmer.

Two further caveats worth stating plainly:

  • Interested authorship. Much of the foundational GHK-Cu literature is authored or co-authored by researchers with long-standing commercial ties to copper-peptide products. That doesn't make the science wrong, but it means independent replication carries more weight than another review from the same lineage.
  • Review ≠ trial. A large share of what circulates as "GHK-Cu research" is narrative review articles restating earlier animal and cell work, not new human data.

The delivery problem: why "penetrates the skin" is doing heavy lifting

GHK-Cu is a small peptide, but "small" in peptide terms is still large by the standards of what passively crosses intact stratum corneum. It is also hydrophilic and carries charge — the two properties the skin barrier is best at excluding. Lipophilic, low-molecular-weight molecules cross reasonably well; charged water-loving ones generally don't, or do so at a fraction of the applied dose.

That has three practical consequences that rarely make it into product copy:

1. Formulation matters more than concentration

A high "GHK-Cu %" on a label means little if the vehicle doesn't help the molecule partition into the skin. Delivery systems, pH and the presence of competing chelators change the picture far more than a percentage does.

2. Copper chemistry is fragile

The copper in GHK-Cu is held in a coordination complex. Strong reducing agents and competing chelators — the sort of thing found in some high-strength vitamin C formulations — can plausibly disturb that complex. The commonly repeated advice not to layer copper peptides with strong ascorbic acid is chemically reasonable, but we're not aware of controlled human data demonstrating a clinical difference either way. Treat it as prudent chemistry, not proven fact.

3. Depth ≠ destination

Even where a peptide reaches the viable epidermis, that's not the same as reaching the dermal fibroblasts that produce the collagen most claims are about. This is the step where in vitro results and topical outcomes most often part company.

What the human evidence does and doesn't cover

There are controlled cosmetic studies of copper-peptide-containing topicals reporting improvements in measures like fine lines and skin appearance, and GHK-Cu has a long safety record in leave-on cosmetic use. That is a legitimate, non-trivial evidence base — it's just a cosmetic evidence base, typically small, often industry-run, and measuring appearance endpoints rather than disease outcomes.

What the literature does not currently support:

  • Hair regrowth as an established effect. Copper peptides and copper-peptide analogues have been explored in hair biology for decades, largely in preclinical models and small or unpublished studies. There is no robust, replicated randomised trial base putting GHK-Cu anywhere near minoxidil or finasteride for androgenetic alopecia. Claims otherwise outrun the data.
  • Systemic anti-ageing effects. The observation that plasma GHK levels fall substantially between young adulthood and later life is frequently used to argue for "restoring" it by injection. That's an inference, not a finding. A declining biomarker with age doesn't establish that raising it back does anything useful, and no adequate human trial of injected GHK-Cu exists to settle it.
  • Wound healing at clinical scale. Animal and tissue-model wound work is genuinely interesting and consistent, but it is animal and tissue-model work.

Is GHK-Cu legal in Australia? The topical/injectable split

This is the clearest part of the picture, and it's worth getting exactly right.

Topical cosmetic use is legal. GHK-Cu appears in leave-on skincare sold openly in Australia. Cosmetic ingredients here are regulated as industrial chemicals through AICIS, and copper peptide serums and creams sit squarely within that framework.

Injectable GHK-Cu is a different matter. It is not an approved therapeutic good in Australia. The TGA's April 2026 alert on unapproved peptides names GHK-Cu among compounds being supplied and promoted outside the approved-medicines system. In practical terms: no ARTG registration, no assessed manufacturing quality, no evaluated dosing, and no Australian consumer protections that come with an approved product. Supplying or advertising it as a therapeutic good without approval is not lawful, regardless of how it's labelled online.

A related caution for anyone doing their own reading: peptide entries on trial registries are not automatically real. Registry listings exist that use plausible-sounding sponsor names and "recruiting" status but don't correspond to any verifiable organisation. Before you treat a registry record as evidence, check that the sponsor is an institution that demonstrably exists.

More background on this compound sits on our GHK-Cu profile, and you can compare it against other compounds in the peptides library. If you'd like new evidence and TGA developments summarised as they land, join the free updates list.

The honest summary

GHK-Cu is one of the better-characterised cosmetic peptides in terms of mechanism, and one of the least-characterised in terms of hard clinical outcomes. Topically, it's a low-risk ingredient with modest cosmetic evidence and enormous mechanistic hype attached. Systemically, it's an unapproved injectable whose entire rationale rests on preclinical inference. Those two sentences describe two very different risk profiles, and the marketing routinely blurs them into one.

FAQ

What is GHK-Cu used for?

Topically, it's used as a cosmetic skincare ingredient aimed at skin appearance, fine lines and general skin quality, with a small controlled-study base behind it. Most other claimed uses — hair regrowth, wound healing, systemic anti-ageing — rest on cell-culture and animal work rather than human trials.

Is GHK-Cu legal in Australia?

Topical cosmetic GHK-Cu is legal and widely sold, regulated as an industrial chemical. Injectable GHK-Cu is not an approved therapeutic good and was named in the TGA's April 2026 alert on unapproved peptides.

Does GHK-Cu actually penetrate the skin?

It's a hydrophilic, charged peptide, and the stratum corneum is specifically good at blocking that class of molecule, so absorption depends heavily on the formulation rather than the stated percentage. How much reaches dermal fibroblasts in intact human skin remains poorly quantified in public data.

Does GHK-Cu regrow hair?

There's no robust, replicated randomised trial evidence supporting GHK-Cu for hair regrowth. The interest comes from preclinical hair-follicle work and copper-peptide analogues, which is a hypothesis rather than a demonstrated effect.

Sources

This article is general information, not medical advice. retatrutide.net.au is independent and sells nothing. Topical cosmetic GHK-Cu is legal in Australia; injectable GHK-Cu is not an approved therapeutic good here. Speak with a qualified Australian health professional before acting on anything you read.